StockData

BillionToOne vs Fulgent Genetics

BLLN and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLLN and FLGT compare

BillionToOne is the larger company, worth 7.3 times as much as Fulgent Genetics ($5.0B against $679M).

BillionToOne grew revenue faster over the last twelve months (71.9% versus 4.7% for Fulgent Genetics).

BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −27.5% at Fulgent Genetics.

BillionToOne scores higher on the StockData Score (11 against 8 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLLNFLGT
Size and price
Market cap$5.0B$679M
Share price$105.15$24.66
Change, 1 year3.3%−15.2%
Change, 5 years–−73.8%
Beta (5Y)−0.040.89
Employees7131,300
StockData Score
Total score11 (better)8
Valuation score03 (better)
Growth score3 (better)0
Performance score2 (better)1
Health score6 (better)4
Dividend score00
Valuation
P/S11.4×2.1× (better)
P/B8.8×0.7× (better)
EV/EBITDA84.8×–
P/FCF146×–
FCF yield0.68% (better)−0.21%
Fair value–$46.08
Margin of safety–46.5%
Growth
Revenue growth (TTM)71.9% (better)4.7%
Revenue growth, 5Y average–−5.2%
Profitability
Gross margin71.4% (better)33.8%
Operating margin10.2% (better)−39.2%
Net margin11.3% (better)−27.5%
FCF margin7.8% (better)−0.42%
Return on equity30.2% (better)−8.6%
Return on invested capital–−12.0%
Financial health
Debt / equity0.000.00 (better)
Interest coverage1655× (better)−1307.9×
Current ratio11.25 (better)5.34
Altman Z-score16.67 (better)5.18
Piotroski F-score8 (better)4
Dividends and buybacks
Buyback yield–9.5%
Shareholder yield0.00%9.5% (better)
Ownership
Held by institutions32.4%57.0%
Held by insiders55.7%39.5%
Insider net buying, 12 months−$58.5M−$286K (better)
Short interest, % of float14.2%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.